Aurinia Pharmaceuticals Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent
Aurinia Pharmaceuticals Inc. (AUPH) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent of 106.30% for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-02-26
- Aurinia Pharmaceuticals Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2024 was 106.30%.
- Aurinia Pharmaceuticals Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2023 was -13.80%.
- Aurinia Pharmaceuticals Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2022 was -8.10%, a 280.00% decline from fiscal 2021.
- Aurinia Pharmaceuticals Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2021 was 4.50%, a 0.00% change from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month as first filed |
|---|---|---|
| 2024-12-31 | 106.30% 10-K · filed 2026-02-26 | |
| 2023-12-31 | -13.80% 10-K · filed 2026-02-26 | 13.80% 10-K · filed 2024-02-15 |
| 2022-12-31 | -8.10% 10-K · filed 2025-02-27 | 8.10% 10-K · filed 2023-02-28 |
| 2021-12-31 | 4.50% 10-K · filed 2024-02-15 | |
| 2020-12-31 | 4.50% 10-K · filed 2023-02-28 | |
| 2019-12-31 | 2.10% 10-K · filed 2022-02-28 | |
| 2018-12-31 | 3.50% 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |